Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Acarix ABACIXF -28.93%37 Operating Cash Flow per Share is $-0.00 as of Jun. 2026. GuruFocus rates ACIXF with a GF Score™ of 37/100 and a GF Value™ of $0.02 (Fairly Valued). The stock has 1 warning sign investors should review. Among 650 Medical Devices & Instruments companies, Acarix AB ranks better than 86.62% on this metric.
Acarix AB's operating cash flow per share for the
three
months ended in Jun. 2026 was $-0.00.
Acarix AB's operating cash flow per share for the trailing twelve months (TTM) ended in Jun. 2026 was $-0.00.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 51.30% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 38.30% per year.
During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 21.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Acarix AB's Operating Cash Flow per Share or its related term are showing as below:
ACIXF'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -62.4 Med: 22.8 Max: 51.3
Current: 51.3
During the past 12 years, Acarix AB's highest 3-Year average Operating Cash Flow per Share Growth Rate was 51.30% per year. The lowest was -62.40% per year. And the median was 22.80% per year.
ACIXF's 3-Year OCF Growth Rate is ranked better than 86.62% of 650
companies
in the Medical Devices & Instruments industry
Industry Median: 12.2
vs ACIXF: 51.30
Acarix AB Operating Cash Flow per Share Related Terms
Acarix AB Operating Cash Flow per Share Historical Data
* Premium members only.
The historical data trend for Acarix AB's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ACIXF vs ABT, SYK, MDT: Operating Cash Flow per Share Comparison
For the Medical Devices subindustry, Acarix AB's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acarix AB Price-to-Operating-Cash-Flow vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Acarix AB's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Acarix AB's Price-to-Operating-Cash-Flow falls into.
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Operating Cash Flow per Share of $-0.00 mean?
Acarix AB (ACIXF) has a Operating Cash Flow per Share of $-0.00 as of Jun. 2026. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Acarix AB and its competitors. According to the industry distribution chart, Acarix AB ranks #87 out of 650 companies in the Medical Devices & Instruments industry, placing it in the top 13.4%.
Is Acarix AB's Operating Cash Flow per Share too high?
Acarix AB's current Operating Cash Flow per Share is $-0.00. Based on the distribution chart, Acarix AB ranks #87 out of 650 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Acarix AB has a GF Score™ of 37/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Acarix AB's Operating Cash Flow per Share compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Acarix AB ranks #87 out of 650 companies for Operating Cash Flow per Share. This places Acarix AB in the top 13% of its industry — outperforming the majority of peers. The industry median Operating Cash Flow per Share is 12.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Cash Flow per Share for a Medical Devices & Instruments company?
The median Operating Cash Flow per Share among Medical Devices & Instruments companies is 12.20, based on 650 companies in the industry. Companies in the top quartile (top 25%) have a Operating Cash Flow per Share significantly above this median, while those in the bottom quartile fall well below. However, Operating Cash Flow per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Cash Flow per Share mean?
A high Operating Cash Flow per Share can signal that a stock is expensive relative to its fundamentals. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Acarix AB and its competitors. For the Medical Devices & Instruments industry, the median Operating Cash Flow per Share is 12.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Acarix AB's current Operating Cash Flow per Share is $-0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acarix AB stock overvalued right now?
Based on GuruFocus' analysis, Acarix AB (ACIXF) is currently considered Fairly Valued. The stock's GF Value™ is $0.02, compared to a current price of $0.02 — trading 0.5% below its estimated fair value. The current Operating Cash Flow per Share is $-0.00. Acarix AB's overall GF Score™ is 37/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Cash Flow per Share calculated?
Operating Cash Flow per Share is calculated from a company's financial statements. For Acarix AB (ACIXF), the current Operating Cash Flow per Share is $-0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Acarix AB (ACIXF) Overvalued in 2026?
Based on GuruFocus' analysis, Acarix AB stock appears to be undervalued.
The current stock price of $0.02 is trading 0.5% below its estimated GF Value™ of $0.02.
GuruFocus considers Acarix AB to be Fairly Valued.
Key valuation signals for ACIXF:
Operating Cash Flow per Share: $-0.00
GF Value™: $0.02 vs. price of $0.02 (0.5% below fair value)
No single metric tells the full story. See the ACIXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Acarix AB is a Swedish medical technology company that develops solutions for rapid AI-based exclusion of coronary artery disease (CAD). Its CE-marked CADScor System, which has also received DeNovo approval from the FDA, is intended for patients experiencing chest pain with suspected coronary artery disease and is designed to help reduce millions of cases of unnecessary, invasive, and costly diagnostics. Acarix recommends the CADScor System as a first-line diagnostic tool that uses sensitive acoustics and computational processing to analyze coronary blood flow to rule out coronary artery disease (CAD), with a majority certainty at the point of care. Geographically, the company generates maximum revenue from the United States, and the rest from Germany, Sweden, Iraq, and other regions.
37GF Score
Get the complete analysis for ACIXF
Operating Cash Flow per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACIXF has been successfully added to your 
